Zobrazeno 61 - 70
of 3 851
pro vyhledávání: '"35"'
Autor:
Francesco Raspagliesi, Luis Chiva, Andrea Dell'Acqua, Baldo Gisone, Giorgio Bogani, Antonino Ditto, Ciro Pinelli, Fabio Ghezzi, Jvan Casarin
Publikováno v:
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society. 30(7)
ObjectiveRecent evidence has suggested that laparoscopic radical hysterectomy is associated with an increased risk of recurrence in comparison with open abdominal radical hysterectomy. The aim of our study was to identify patterns of recurrence after
Autor:
Henriette J. G. Arts, Corine M. Koopmans, Anne-Floor W. Pouwer, Johanna M.A. Pijnenborg, Joanna IntHout, Joanne A. de Hullu
Publikováno v:
Surgical Oncology-Oxford, 35, pp. 149-155
Surgical Oncology-Oxford, 35, 149-155
Surgical oncology-Oxford, 35, 149-155. ELSEVIER SCI LTD
Surgical Oncology-Oxford, 35, 149-155
Surgical oncology-Oxford, 35, 149-155. ELSEVIER SCI LTD
Background: Inguinofemoral lymphadenectomy (IFL) is part of the surgical treatment of different malignancies of the genital tract and/or the lower limb including vulvar carcinoma, penile carcinoma and melanoma. IFL is associated with morbidity in up
Publikováno v:
European Journal of Surgical Oncology, 45(12), 2295-2301. ELSEVIER SCI LTD
Introduction: Interest in adoption of a prehabilitation programme in management of colorectal cancer is increasing, but current waiting time targets leave no opening for intervention. Prompt treatment following diagnosis is demanded but defending evi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a1432aeb742c080f30bf5dc2bc123bb
https://cris.maastrichtuniversity.nl/en/publications/f36d372a-35d5-444d-943d-f42040bb0fd2
https://cris.maastrichtuniversity.nl/en/publications/f36d372a-35d5-444d-943d-f42040bb0fd2
Publikováno v:
Radiation Oncology, Vol 13, Iss 1, Pp 1-11 (2018)
Radiation Oncology (London, England)
Radiation Oncology (London, England)
Background In this pooled 2-center series LINAC radiosurgery (SRS) has been applied as a treatment option for a subset of refractory trigeminal neuralgia (TN) patients. This study approached to retrospectively assess the efficacy and safety of LINAC
Publikováno v:
PLoS ONE
PLoS ONE, Vol 15, Iss 3, p e0230113 (2020)
PLoS ONE, Vol 15, Iss 3, p e0230113 (2020)
Background The drawback of the delta-shaped gastroduodenostomy (DSG) in totally laparoscopic distal gastrectomy (TLDG) is the presence of intraoperative duodenal injury and postoperative anastomotic stenosis, which can occur due to a relatively short
Autor:
Michael P. Kim, Thomas A. Aloia, Ching Wei D. Tzeng, Laura R. Prakash, Graciela M. Nogueras-Gonzalez, Jason B. Fleming, Jeffrey E. Lee, Rebecca A. Snyder, Jean Nicolas Vauthey, Matthew H.G. Katz
Publikováno v:
Journal of Surgical Oncology. 117:1648-1654
BACKGROUND AND OBJECTIVES Venous patency rates after pancreaticoduodenectomy (PD) with portal vein (PV) resection are not well established, and the oncologic impact of portal vein thrombosis (PVT) is unknown. The primary aim of this study was to dete
Autor:
Akiyo Taneichi, Shizuo Machida, Chikako Yoshida, Yoshifumi Takahashi, Suzuyo Takahashi, Shigeki Matsubara, Takahiro Yoshiba, Yasushi Saga, Hiroyuki Fujiwara, Yuji Takei
Publikováno v:
International Journal of Clinical Oncology. 23:930-935
Although there have been several reports regarding the significance of staging lymphadenectomy for early stage ovarian clear cell carcinoma (CCC) patients, there have been few reports focusing on the number of removed lymph nodes. The aim of this stu
Publikováno v:
European Journal of Surgical Oncology. 43:2112-2118
Although CA125 and the tumor immune response have been reported to be associated with pancreatic cancer, their prognostic value for advanced pancreatic cancer patients undergoing chemotherapy remain uncertain. We thus studied the prognostic value of
Autor:
Gerald H. Clamon, Mark A. Socinski, Neal Ready, Ying Zhang, Everett E. Vokes, Walter J. Curran, Benjamin Movsas, Xiaofei Wang, Steven E. Schild, Jeffrey D. Bradley, Joan H. Schiller, George R. Blumenschein, Thomas E. Stinchcombe, Herbert Pang, Harvey J. Cohen, Ramaswamy Govindan, Wallace Akerley, Karen Kelly
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 35, iss 25
Stinchcombe, TE; Zhang, Y; Vokes, EE; Schiller, JH; Bradley, JD; Kelly, K; et al.(2017). Pooled analysis of individual patient data on concurrent chemoradiotherapy for stage III non-small-cell lung cancer in elderly patients compared with younger patients who participated in US national cancer institute cooperative group studies. Journal of Clinical Oncology, 35(25), 2885-2892. doi: 10.1200/JCO.2016.71.4758. UC Davis: Retrieved from: http://www.escholarship.org/uc/item/0j4582gf
Stinchcombe, TE; Zhang, Y; Vokes, EE; Schiller, JH; Bradley, JD; Kelly, K; et al.(2017). Pooled analysis of individual patient data on concurrent chemoradiotherapy for stage III non-small-cell lung cancer in elderly patients compared with younger patients who participated in US national cancer institute cooperative group studies. Journal of Clinical Oncology, 35(25), 2885-2892. doi: 10.1200/JCO.2016.71.4758. UC Davis: Retrieved from: http://www.escholarship.org/uc/item/0j4582gf
Purpose Concurrent chemoradiotherapy is standard treatment for patients with stage III non–small-cell lung cancer. Elderly patients may experience increased rates of adverse events (AEs) or less benefit from concurrent chemoradiotherapy. Patients a
Autor:
Maximilian Hochmair, Sang-We Kim, Frank G. Haluska, Edward S. Kim, Luis Paz-Ares Rodríguez, Karen L. Reckamp, Howard West, Egbert F. Smit, William M. Reichmann, David Kerstein, D. Ross Camidge, Rudolf M. Huber, Scott N. Gettinger, Karin Holmskov Hansen, Natasha B. Leighl, Marcello Tiseo, Corey J. Langer, Myung-Ju Ahn, Dong Wan Kim, Harry J.M. Groen
Publikováno v:
Kim, D W, Tiseo, M, Ahn, M J, Reckamp, K L, Hansen, K H, Kim, S W, Huber, R M, West, H L, Groen, H J M, Hochmair, M J, Leighl, N B, Gettinger, S N, Langer, C J, Rodríguez, L G P A, Smit, E F, Kim, E S, Reichmann, W, Haluska, F G, Kerstein, D & Camidge, D R 2017, ' Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer : A randomized, multicenter phase II trial ', Journal of Clinical Oncology, vol. 35, no. 22, pp. 2490-2498 . https://doi.org/10.1200/JCO.2016.71.5904
Journal of Clinical Oncology, 35(22), 2490-2498. AMER SOC CLINICAL ONCOLOGY
Kim, D-W, Tiseo, M, Ahn, M-J, Reckamp, K L, Hansen, K H, Kim, S-W, Huber, R M, West, H L, Groen, H J M, Hochmair, M J, Leighl, N B, Gettinger, S N, Langer, C J, Paz-Ares Rodríguez, L G, Smit, E F, Kim, E S, Reichmann, W, Haluska, F G, Kerstein, D & Camidge, D R 2017, ' Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer : A Randomized, Multicenter Phase II Trial ', Journal of Clinical Oncology, vol. 35, no. 22, pp. 2490-2498 . https://doi.org/10.1200/JCO.2016.71.5904
Journal of Clinical Oncology, 35(22), 2490-2498. American Society of Clinical Oncology
Journal of Clinical Oncology, 35(22), 2490-2498. AMER SOC CLINICAL ONCOLOGY
Kim, D-W, Tiseo, M, Ahn, M-J, Reckamp, K L, Hansen, K H, Kim, S-W, Huber, R M, West, H L, Groen, H J M, Hochmair, M J, Leighl, N B, Gettinger, S N, Langer, C J, Paz-Ares Rodríguez, L G, Smit, E F, Kim, E S, Reichmann, W, Haluska, F G, Kerstein, D & Camidge, D R 2017, ' Brigatinib in Patients With Crizotinib-Refractory Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer : A Randomized, Multicenter Phase II Trial ', Journal of Clinical Oncology, vol. 35, no. 22, pp. 2490-2498 . https://doi.org/10.1200/JCO.2016.71.5904
Journal of Clinical Oncology, 35(22), 2490-2498. American Society of Clinical Oncology
Purpose Most crizotinib-treated patients with anaplastic lymphoma kinase gene ( ALK)–rearranged non–small-cell lung cancer (ALK-positive NSCLC) eventually experience disease progression. We evaluated two regimens of brigatinib, an investigational